Table 2.
Comparison of COVIDs-19 and non-COVID-19 outcomes.
| COVID-19 (n = 59) | Non-COVID-19 (n = 12) | P-value | |
|---|---|---|---|
| Number of infusion events | 85 | 12 | N/A |
| Rocuronium maintenance continuous infusion rate, mcg/kg/mina | 4.9 (2.84-7.61) | 3.6 (2.27-4.17) | .03 |
| Initial continuous infusion rate, mcg/kg/mina | 3 (3-5) | 3 (3-5) | N/A |
| Duration of therapy, hoursa | 53.2 (27.49-92.51) | 23.7 (13.85-92.21) | .06 |
| Cumulative dose, grama | 1.19 (.47-2.74) | .33 (.15-4.82) | .01 |
| PaO2/FiO2a | 118.5 (100-162.13) | 179 (134.35-355) | .02 |
| ARDS classificationb | |||
| Mild | 4 (7) | 1 (8) | 1 |
| Moderate | 39 (66) | 5 (24) | .19 |
| Severe | 15 (25) | 2 (17) | .71 |
| >300 | 1 (2) | 4 (33) | .002 |
Abbreviations: ARDS, acute respiratory distress syndrome; FiO2, Fraction of inspired oxygen; PaO2, Partial pressure of oxygen.
aMedian (IQR),
bn (%).